Barclays raised the firm’s price target on Cardinal Health (CAH) to $258 from $243 and keeps an Overweight rating on the shares. The firm upped estimates to reflect strength across Cardinal’s business. The company’s guidance and consensus estimates “remain in a reasonable place,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $256 from $237 at Wells Fargo
- Cardinal Health price target raised to $255 from $245 at Morgan Stanley
- Cardinal Health price target raised to $252 from $250 at Baird
- Cardinal Health price target raised to $260 from $250 at UBS
- Cardinal Health price target raised to $260 from $250 at Evercore ISI